Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively active in the majority of patients with AML. Given...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyu, Su, Yongwei, Madlambayan, Gerard, Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Ma, Jun, Knight, Tristan, Wang, Guan, Wang, Yue, Yang, Jay, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821619/
https://www.ncbi.nlm.nih.gov/pubmed/30819918
http://dx.doi.org/10.3324/haematol.2018.201343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821619/
https://www.ncbi.nlm.nih.gov/pubmed/30819918
http://dx.doi.org/10.3324/haematol.2018.201343

Ejemplares similares